<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for preventing thrombosis in solid organ transplant recipients - Surianarayanan, V - 2021 | Cochrane Library</title> <meta content="Interventions for preventing thrombosis in solid organ transplant recipients - Surianarayanan, V - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011557.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for preventing thrombosis in solid organ transplant recipients - Surianarayanan, V - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011557.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011557.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for preventing thrombosis in solid organ transplant recipients" name="citation_title"/> <meta content="Vignesh Surianarayanan&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Thomas J Hoather" name="citation_author"/> <meta content="Newcastle University" name="citation_author_institution"/> <meta content="Samuel J Tingle" name="citation_author"/> <meta content="Newcastle University and Cambridge University" name="citation_author_institution"/> <meta content="Emily R Thompson" name="citation_author"/> <meta content="The Freeman Hospital" name="citation_author_institution"/> <meta content="John Hanley" name="citation_author"/> <meta content="Newcastle upon Tyne Acute Hospitals" name="citation_author_institution"/> <meta content="Colin H Wilson" name="citation_author"/> <meta content="The Freeman Hospital" name="citation_author_institution"/> <meta content="colin.wilson6@nhs.net" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011557.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/03/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011557.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011557.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011557.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects, therapeutic use]; Aspirin [therapeutic use]; Bias; Dipyridamole [therapeutic use]; Hemorrhage [chemically induced]; Heparin [adverse effects, therapeutic use]; Heparin, Low-Molecular-Weight [adverse effects, therapeutic use]; Kidney Transplantation [*adverse effects, statistics &amp; numerical data]; Liver Transplantation [*adverse effects, statistics &amp; numerical data]; Placebos [therapeutic use]; Platelet Aggregation Inhibitors [therapeutic use]; Postoperative Complications [*prevention &amp; control]; Randomized Controlled Trials as Topic; Thrombosis [*prevention &amp; control]; *Transplant Recipients; Warfarin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011557.pub2&amp;doi=10.1002/14651858.CD011557.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011557\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011557\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011557.pub2",title:"Interventions for preventing thrombosis in solid organ transplant recipients",firstPublishedDate:"Mar 15, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011557.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011557.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011557.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011557.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011557.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011557.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011557.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011557.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011557.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011557.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3626 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011557.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0093"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-sec-0085"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/appendices#CD011557-sec-0100"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/table_n/CD011557StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/table_n/CD011557StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for preventing thrombosis in solid organ transplant recipients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Vignesh Surianarayanan and Thomas Hoather contributed equally to this review, and are duly acknowledged as joint lead authors"><a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#CD011557-cr-0004">Vignesh Surianarayanan</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#CD011557-cr-0005">Thomas J Hoather</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#CD011557-cr-0006">Samuel J Tingle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#CD011557-cr-0007">Emily R Thompson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#CD011557-cr-0008">John Hanley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information#CD011557-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Colin H Wilson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information/en#CD011557-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 March 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011557.pub2">https://doi.org/10.1002/14651858.CD011557.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011557-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011557-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011557-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011557-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011557-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011557-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011557-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011557-abs-0001" lang="en"> <section id="CD011557-sec-0001"> <h3 class="title" id="CD011557-sec-0001">Background</h3> <p>Graft thrombosis is a well‐recognised complication of solid organ transplantation and is one of the leading causes of graft failure. Currently there are no standardised protocols for thromboprophylaxis. Many transplant units use unfractionated heparin (UFH) and fractionated heparins (low molecular weight heparin; LMWH) as prophylaxis for thrombosis. Antiplatelet agents such as aspirin are routinely used as prophylaxis of other thrombotic conditions and may have a role in preventing graft thrombosis. However, any pharmacological thromboprophylaxis comes with the theoretical risk of increasing the risk of major blood loss following transplant. This review looks at benefits and harms of thromboprophylaxis in patients undergoing solid organ transplantation. </p> </section> <section id="CD011557-sec-0002"> <h3 class="title" id="CD011557-sec-0002">Objectives</h3> <p>To assess the benefits and harms of instituting thromboprophylaxis to patients undergoing solid organ transplantation. </p> </section> <section id="CD011557-sec-0003"> <h3 class="title" id="CD011557-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant Register of Studies up to 10 November 2020 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. </p> </section> <section id="CD011557-sec-0004"> <h3 class="title" id="CD011557-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) and quasi‐RCTs designed to examine interventions to prevent thrombosis in solid organ transplant recipients. All donor types were included (donor after circulatory (DCD) and brainstem death (DBD) and live transplantation). There was no upper age limit for recipients in our search. </p> </section> <section id="CD011557-sec-0005"> <h3 class="title" id="CD011557-sec-0005">Data collection and analysis</h3> <p>The results of the literature search were screened and data collected by two independent authors. Dichotomous outcome results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Random effects models were used for data analysis. Risk of bias was independently assessed by two authors using the risk of bias assessment tool. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. </p> </section> <section id="CD011557-sec-0006"> <h3 class="title" id="CD011557-sec-0006">Main results</h3> <p>We identified nine studies (712 participants). Seven studies (544 participants) included kidney transplant recipients, and two studies (168 participants) included liver transplant recipients. We did not identify any study enrolling heart, lung, pancreas, bowel, or any other solid organ transplant recipient. Selection bias was high or unclear in eight of the nine studies; five studies were at high risk of bias for performance and/or detection bias; while attrition and reporting biases were in general low or unclear. </p> <p>Three studies (180 participants) primarily investigated heparinisation in kidney transplantation. Only two studies reported on graft vessel thrombosis in kidney transplantation (144 participants). These small studies were at high risk of bias in several domains and reported only two graft thromboses between them; it therefore remains unclear whether heparin decreases the risk of early graft thrombosis or non‐graft thrombosis (very low certainty). </p> <p>UFH may make little or no difference versus placebo to the rate of major bleeding events in kidney transplantation (3 studies, 155 participants: RR 2.92, 95% CI 0.89 to 9.56; I² = 0%; low certainty evidence). Sensitivity analysis using a fixed‐effect model suggested that UFH may increase the risk of haemorrhagic events compared to placebo (RR 3.33, 95% CI 1.04 to 10.67, P = 0.04). Compared to control, any heparin (including LMWH) may make little or no difference to the number of major bleeding events (3 studies, 180 participants: RR 2.70, 95% CI 0.89 to 8.19; I² = 0%; low certainty evidence) and had an unclear effect on risk of readmission to intensive care (3 studies, 180 participants: RR 0.68, 95% CI 0.12 to 3.90, I² = 45%; very low certainty evidence). The effect of heparin on our other outcomes (including death, patient and graft survival, transfusion requirements) remains unclear (very low certainty evidence). </p> <p>Three studies (144 participants) investigated antiplatelet interventions in kidney transplantation: aspirin versus dipyridamole (1), and Lipo‐PGE<sub>1</sub> plus low‐dose heparin to "control" in patients who had a diagnosis of acute rejection (2). None of these reported on early graft thromboses. The effect of aspirin, dipyridamole and Lipo PGE<sub>1</sub> plus low‐dose heparin on any outcomes is unclear (very low certainty evidence). </p> <p>Two studies (168 participants) assessed interventions in liver transplants. One compared warfarin versus aspirin in patients with pre‐existing portal vein thrombosis and the other investigated plasmapheresis plus anticoagulation. Both studies were abstract‐only publications, had high risk of bias in several domains, and no outcomes could be meta‐analysed. Overall, the effect of any of these interventions on any of our outcomes remains unclear with no evidence to guide anti‐thrombotic therapy in standard liver transplant recipients (very low certainty evidence). </p> </section> <section id="CD011557-sec-0007"> <h3 class="title" id="CD011557-sec-0007">Authors' conclusions</h3> <p>Overall, there is a paucity of research in the field of graft thrombosis prevention. Due to a lack of high quality evidence, it remains unclear whether any therapy is able to reduce the rate of early graft thrombosis in any type of solid organ transplant. UFH may increase the risk of major bleeding in kidney transplant recipients, however this is based on low certainty evidence. There is no evidence from RCTs to guide anti‐thrombotic strategies in liver, heart, lung, or other solid organ transplants. Further studies are required in comparing anticoagulants, antiplatelets to placebo in solid organ transplantation. These should focus on outcomes such as early graft thrombosis, major haemorrhagic complications, return to theatre, and patient/graft survival. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011557-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011557-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011557-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011557-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011557-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011557-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011557-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011557-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011557-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011557-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011557-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011557-abs-0002" lang="en"> <h3>Therapies to reduce the risk of blood clots forming in transplanted organs</h3> <p><b>What is the issue?</b> </p> <p>After an organ is transplanted there is a risk of blood clot forming in an artery supplying blood to the organ, or a vein which drains blood from the organ. If a blood clot forms (termed "graft thrombosis") this prevents blood flow, which can cause the organ to fail. There are lots of therapies which aim to lower the ability of the blood to clot (sometimes called "blood thinners"). It is unclear whether these therapies are able to prevent graft thrombosis, or if they increase the risk of major bleeding. </p> <p><b>What did we do?</b> </p> <p>We performed a rigorous search for studies which compared different blood thinning therapies in patients receiving an organ transplant. We were especially interested in studies which reported on graft thrombosis rates, and also on complications of blood thinners, specifically the rate of major bleeding events. Data from multiple studies were combined if possible. </p> <p><b>What did we find?</b> </p> <p>We identified nine studies (712 patients) that met our inclusion criteria; the quality of these studies was generally low. There were only two small studies which reported graft thrombosis in kidney transplants. One blood thinner called "unfractionated heparin" may increase the risk of bleeding following kidney transplantation, but this finding is of low certainty. The effect of blood thinners on our other outcomes (need for further surgery or readmission to intensive care, blood transfusion requirements, hospital stay, other side effects, blood clots elsewhere in the body, longevity of the transplanted organ and death) in kidney transplantation remains unclear. </p> <p>Two studies investigated various blood thinners in two unique groups of patients who received a liver transplant. It remains unclear whether any of the blood thinning treatments they tested have any effect on graft thrombosis or major bleeding. The effect of blood thinners on other outcomes in liver transplant recipients also remains unclear. </p> <p>There were no studies which investigated blood thinners in heart, lung, pancreas, or any other organ transplantation. </p> <p><b>Conclusions</b> </p> <p>There is a lack of evidence to guide the use of medications to prevent blood clots in transplanted organs. New research is needed to assess treatments to prevent blood clots, and also to investigate the risks of these treatments, such as major bleeding. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011557-sec-0093" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011557-sec-0093"></div> <h3 class="title" id="CD011557-sec-0094">Implications for practice</h3> <section id="CD011557-sec-0094"> <p>Overall, it remains unclear whether any anti‐thrombotic therapy has an effect on the rate of early graft thrombosis in any solid organ transplants (very low certainty evidence). </p> <section id="CD011557-sec-0095"> <h5 class="title">Kidney transplant</h5> <p>The impact of anticoagulation with heparin on rate of graft thrombosis remains unclear (very low certainty evidence). There is poor quality evidence which suggests that UFH may increase the risk of major bleeding events in renal transplants (low certainty evidence). The effect of LMWH on bleeding events remains uncertain (very low certainty evidence). The risk of readmission to ITU, blood transfusion requirements, mortality, and patient/graft survival after heparinisation remain uncertain due to very low certainty evidence. There is no evidence found on the effect of heparinisation on the extent of hospital stays. Given the possibility of haemorrhagic complications and overall uncertainty of impact on graft thrombosis, there is insufficient evidence to guide routine postoperative use of UFH in renal transplantation. </p> <p>There is no evidence on the impact of antiplatelet intervention on early graft thrombosis risk. The evidence comparing buffered aspirin to dipyridamole in relation to effect on risk of bleeding events, risk of readmission to intensive care and blood transfusion requirements is of very low certainty so these effects remain unclear. The effect of Lipo PGE<sub>1</sub> therapy on patient survival rates and graft survival rates is uncertain due to very low certainty evidence. There is a lack of evidence on any antiplatelet strategy in kidney transplantation to guide clinical decision making. </p> </section> <section id="CD011557-sec-0096"> <h5 class="title">Liver transplantation</h5> <p>Studies have only been performed on specific subgroups; those with pre‐existing portal vein thrombosis and those with antiphospholipid antibodies or lupus anticoagulant plus other thrombosis risk factors. It is unclear whether any anti‐thrombosis strategies (including aspirin, warfarin, and plasmapheresis) have an effect on; graft thrombosis rate, major bleeding rate, return to theatre/intensive care, blood transfusion requirements or any of our secondary outcomes (very low certainty evidence). </p> </section> </section> <h3 class="title" id="CD011557-sec-0097">Implications for research</h3> <section id="CD011557-sec-0097"> <p>Overall, there is a paucity of research in the field of pharmacological prevention of graft thromboses. The limited available evidence is at high risk of bias, and most relevant studies on graft thrombosis were completed more than 30 years ago or only available as conference abstracts. Therefore, further studies are required in comparing anticoagulants (e.g. heparin) versus antiplatelets (e.g. aspirin) against placebos in solid organ transplantation, focusing on outcomes such as early graft thrombosis, major haemorrhagic complications, death, and patient/graft survival. All studies should be large, multicentre, and randomised to ensure minimal bias and sufficient statistical power to detect significant differences. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011557-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011557-sec-0008"></div> <div class="table" id="CD011557-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus placebo for preventing thrombosis in kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Heparin versus placebo for preventing thrombosis in kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/><b>Setting:</b> Australia, Egypt, UK<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early graft thrombosis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported no difference between groups.</p> <p>Effect on early graft thrombosis remains unclear</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events: unfractionated heparin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1,000<br/>(33 to 359) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.92<br/>(0.89 to 9.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfractionated heparin may increase the risk of bleeding events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events: all heparin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1,000<br/>(33 to 307) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.70<br/>(0.89 to 8.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All heparin may increase the risk of bleeding events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Readmissions to intensive care: all heparin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1,000<br/>(15 to 488) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.12 to 3.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effect on readmission to intensive care remains uncertain</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion requirements</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported no difference between groups</p> <p>Effect on blood transfusion requirements remains unclear</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft and patient survival</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies comparing heparin with control reported on graft or patient survival</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐graft thrombosis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two studies reported no significant differences between groups</p> <p>Effect on non‐graft thrombosis remains unclear</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011557-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011557-sec-0009"></div> <section id="CD011557-sec-0010"> <h3 class="title" id="CD011557-sec-0010">Description of the condition</h3> <p>Graft thrombosis can lead to devastating sequelae in patients receiving organ transplants. Estimates of thrombosis following solid organ transplantation vary according to the organ transplanted and the pre‐existing prothrombotic states. Pancreas transplantation appears to have the highest thrombosis rate of vascularised organ transplants. The reported rate varies from 7% to 27% (<a href="./references#CD011557-bbs2-0013" title="BlundellJ , ShahrestaniS , LendzionR , PleassHJ , HawthorneWJ . Risk factors for early pancreatic allograft thrombosis following simultaneous pancreas-kidney transplantation: a systematic review. Clinical &amp; Applied Thrombosis/Hemostasis2020;26:1076029620942589. [MEDLINE: 33052066]">Blundell 2020</a>; <a href="./references#CD011557-bbs2-0018" title="GilabertR , Fernandez-CruzL , RealMI , RicartMJ , AstudilloE , MontanaX . Treatment and outcome of pancreatic venous graft thrombosis after kidney-pancreas transplantation. British Journal of Surgery2002;89(3):355-60. [MEDLINE: 11872064]">Gilabert 2002</a>; <a href="./references#CD011557-bbs2-0021" title="GruessnerA , SutherlandDE . Pancreas transplantation in the United States (US) and non-US as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clinical Transplants1996:47-67. [MEDLINE: 9286558]">Gruessner 1996</a>; <a href="./references#CD011557-bbs2-0022" title="GruessnerRW , SutherlandDE , TroppmannC , BenedettiE , HakimN , DunnDL , et al. The surgical risk of pancreas transplantation in the cyclosporine era: an overview. Journal of the American College of Surgeons1997;185(2):128-44. [MEDLINE: 9249080]">Gruessner 1997</a>; <a href="./references#CD011557-bbs2-0030" title="KoppWH , LeeuwenCAT , LamDH , HuurmanVAL , FijterJW , SchaapherderAF , et al. Retrospective study on detection, treatment, and clinical outcome of graft thrombosis following pancreas transplantation. Transplant International2018;32(4):410-7. [MEDLINE: 30525250]">Kopp 2018</a>; <a href="./references#CD011557-bbs2-0042" title="TroppmannC , GruessnerAC , DunnDL , SutherlandDE , GruessnerRW . Surgical complications requiring early relaparotomy after pancreas transplantation: a multivariate risk factor and economic impact analysis of the cyclosporine era. Annals of Surgery1998;227(2):255-68. [MEDLINE: 9488525]">Troppmann 1998</a>) following solitary pancreas transplantation, pancreas after kidney or simultaneous pancreas‐kidney transplantation. Graft thrombosis, in the early perioperative period, is largely due to technical failure rather than acute rejection or recipient factors. Poor microvascular flow in the pancreas and hypercoagulability in diabetic patients undergoing transplantation contribute to the risk of graft thrombosis occurring in the splenic and mesenteric veins (<a href="./references#CD011557-bbs2-0035" title="MuthusamyAS , GiangrandePL , FriendPJ . Pancreas allograft thrombosis. Transplantation2010;90(7):705-7. [MEDLINE: 20616765]">Muthusamy 2010</a>) and can affect either the arterial inflow or venous outflow. </p> <p>In kidney transplantation, a study of 1200 consecutive live donor kidney transplants found stenotic or thrombotic complications in 0.9% cases, of which 0.4% were due to kidney artery thrombosis and 0.1% kidney vein thrombosis (<a href="./references#CD011557-bbs2-0036" title="OsmanY , ShokeirA , Ali-el-DeinB , TantawyM , WafaEW , el-DeinAB , et al. Vascular complications after live donor renal transplantation: study of risk factors and effects on graft and patient survival. Journal of Urology2003;169(3):859-62. [MEDLINE: 12576799]">Osman 2003</a>). Rates are similar following deceased donor transplant approximately 0.4% for arterial thrombosis and approximately 2.3% to 3.4% for venous thrombosis (<a href="./references#CD011557-bbs2-0012" title="BakirN , SluiterWJ , PloegRJ , vanSonWJ , TegzessAM . Primary renal graft thrombosis. Nephrology Dialysis Transplantation1996;11(1):140-7. [MEDLINE: 8649623]">Bakir 1996</a>; <a href="./references#CD011557-bbs2-0023" title="HamedMO , ChenY , PaseaL , WatsonPJ , TorpeyN , BradleyJA , et al. Early graft loss after kidney transplantation: risk factors and consequences. American Journal of Transplantation2015;15(6):1632-43. [MEDLINE: 25707303]">Hamed 2015</a>; <a href="./references#CD011557-bbs2-0041" title="SugiMD , AlbadawiH , KnuttinenG , NaiduSG , MathurAK , MossAA , et al. Transplant artery thrombosis and outcomes. Cardiovascular Diagnosis &amp; Therapy2017;7(Suppl 3):S219-27. [MEDLINE: 29399525]">Sugi 2017</a>). In consequence, kidney allograft vascular thrombosis is a relatively rare occurrence and one which is likely to be multifactorial. Possible risk factors may include technical complications such as vascular damage or positioning and co‐morbidities including diabetes mellitus, or a prothrombotic state such as antiphospholipid syndrome (<a href="./references#CD011557-bbs2-0027" title="IrishA . Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. American Journal of Cardiovascular Drugs2004;4(3):139-49. [MEDLINE: 15134466]">Irish 2004</a>). </p> <p>In contrast, hepatic artery thrombosis (incidence 2% to 9% of liver recipients) is a serious and common complication, leading to liver graft loss and urgent retransplantation (<a href="./references#CD011557-bbs2-0033" title="MouradMM , LiosisC , GunsonBK , MergentalH , IsaacJ , MuiesanP , et al. Aetiology and management of hepatic artery thrombosis after adult liver transplantation. Liver Transplantation2014;20(6):713-23. [DOI: 10.1002/lt.23874]">Mourad 2014</a>). The incidence of hepatic artery thrombosis is higher in children owing to smaller calibre vasculature and different coagulation parameters (<a href="./references#CD011557-bbs2-0043" title="WozneyP , ZajkoAB , BronKM , PointS , StarzlTE . Vascular complications after liver transplantation: a 5-year experience. AJR. American Journal of Roentgenology1986;147(4):657-63. [MEDLINE: 3529892]">Wozney 1986</a>). Endovascular or operative salvage can be attempted, but most patients ultimately require a further transplant. Often the patient presents with a bile leak or jaundice due to an ischaemic stenosis or leak at the biliary anastomosis. </p> <p>Venous thromboembolism appears to be a particular issue for cardiothoracic transplant patients and this is emphasised in The International Society of Heart and Lung Transplantation Guidelines (<a href="./references#CD011557-bbs2-0015" title="CostanzoMR , DipchandA , StarlingR , AndersonA , ChanM , DesaiS , et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart &amp; Lung Transplantation2010;29(8):914-56. [MEDLINE: 20643330]">Costanzo 2010</a>). For lung transplant recipients, venous thromboembolism can be a significant issue, with a reported incidence of 12.1% in one study (<a href="./references#CD011557-bbs2-0031" title="KroshusTJ , KshettryVR , HertzMI , Morton Bolman RM 3rd. Deep venous thrombosis and pulmonary embolism after lung transplantation. Journal of Thoracic &amp; Cardiovascular Surgery1995;110(2):540-4. [MEDLINE: 7637373]">Kroshus 1995</a>). Furthermore, pulmonary vein thrombosis at the anastomotic site can lead to significant morbidity and graft loss (<a href="./references#CD011557-bbs2-0032" title="LeibowitzDW , SmithCR , MichlerRE , GinsburgM , SchulmanLL , McGregorCC , et al. Incidence of pulmonary vein complications after lung transplantation: a prospective transesophageal echocardiographic study. Journal of the American College of Cardiology1994;24(3):671-5. [MEDLINE: 8077537]">Leibowitz 1994</a>). In thoracic organ transplants almost half of peripheral thromboses originate in the upper limbs (<a href="./references#CD011557-bbs2-0028" title="KahanES , PetersenG , GaughanJP , CrinerGJ . High incidence of venous thromboembolic events in lung transplant recipients. Journal of Heart &amp; Lung Transplantation2007;26(4):339-44. [MEDLINE: 17403474]">Kahan 2007</a>). </p> <p>Chronic graft loss due to thrombosis is of particular concern in the coronary arteries after heart transplantation (3% at one year and 40% at five years) (<a href="./references#CD011557-bbs2-0034" title="MullinsPA , CaryNR , SharplesL , ScottJ , AravotD , LargeSR , et al. Coronary occlusive disease and late graft failure after cardiac transplantation. British Heart Journal1992;68(3):260-5. [MEDLINE: 1389755]">Mullins 1992</a>); although vasculopathy is recognised in all transplant recipients as the major cause of late graft loss and graft thrombosis is the inevitable outcome of chronic rejection. </p> </section> <section id="CD011557-sec-0011"> <h3 class="title" id="CD011557-sec-0011">Description of the intervention</h3> <p>There are currently no standardised protocols to guide thromboprophylactic therapy in the post‐transplant period. Following liver and pancreas transplantation, many advocate the use of subcutaneous or intravenous agents to reduce the risk of thrombosis (<a href="./references#CD011557-bbs2-0033" title="MouradMM , LiosisC , GunsonBK , MergentalH , IsaacJ , MuiesanP , et al. Aetiology and management of hepatic artery thrombosis after adult liver transplantation. Liver Transplantation2014;20(6):713-23. [DOI: 10.1002/lt.23874]">Mourad 2014</a>; <a href="./references#CD011557-bbs2-0035" title="MuthusamyAS , GiangrandePL , FriendPJ . Pancreas allograft thrombosis. Transplantation2010;90(7):705-7. [MEDLINE: 20616765]">Muthusamy 2010</a>) such as low molecular weight heparin (LMWH) and unfractionated heparin (UFH). Dextran D40 is a synthetic colloid with anticoagulant properties that may be as effective as UFH in pancreas transplantation and confer a lower bleeding risk (<a href="./references#CD011557-bbs2-0026" title="InnesA , TingleS , IbrahimI , ThompsonE , BatesL , ManasD , WhiteS , Wilson C. Use of Dextran 40 After Pancreas Transplant May Reduce Early Inflammation and Significant Bleeding Compared to a Heparin-Based Protocol. Transplantation proceedings March 2021;53(2):712-715.">Innes 2021</a>). Many transplant units also advocate this treatment for kidney transplant recipients at increased risk of thrombosis (multiple vessels, donors after cardiac death). Heart transplantation, by necessity, involves a period of cardiopulmonary bypass, and heparin in this period appears to be complicated by a high incidence and prevalence of heparin‐induced platelet antibodies (heparin‐induced thrombocytopenia). Other intravenous therapies, such as dextran colloidal solutions, have also been used to reduce the risk of thrombosis (<a href="./references#CD011557-bbs2-0035" title="MuthusamyAS , GiangrandePL , FriendPJ . Pancreas allograft thrombosis. Transplantation2010;90(7):705-7. [MEDLINE: 20616765]">Muthusamy 2010</a>). </p> <p>Fractionated heparins (LMWH) are now widely used in the hospital setting for prevention of venous thromboembolism in high risk patients. Transplant recipients undergoing major surgery also appear to be at risk of lower and upper limb thrombosis (<a href="./references#CD011557-bbs2-0011" title="AlkhunaiziAM , OlyaeiAJ , BarryJM , deMattosAM , ConlinMJ , LemmersMJ , et al. Efficacy and safety of low molecular weight heparin in renal transplantation. Transplantation1998;66(4):533-4. [MEDLINE: 9734500 ]">Alkhunaizi 1998</a>; <a href="./references#CD011557-bbs2-0014" title="CherianTP , ChiuK , GunsonB , BramhallSR , MayerD , MirzaDF , et al. Pulmonary thromboembolism in liver transplantation: a retrospective review of the first 25 years. Transplant International2010;23(11):1113-9. [MEDLINE: 20497402]">Cherian 2010</a>; <a href="./references#CD011557-bbs2-0028" title="KahanES , PetersenG , GaughanJP , CrinerGJ . High incidence of venous thromboembolic events in lung transplant recipients. Journal of Heart &amp; Lung Transplantation2007;26(4):339-44. [MEDLINE: 17403474]">Kahan 2007</a>; <a href="./references#CD011557-bbs2-0031" title="KroshusTJ , KshettryVR , HertzMI , Morton Bolman RM 3rd. Deep venous thrombosis and pulmonary embolism after lung transplantation. Journal of Thoracic &amp; Cardiovascular Surgery1995;110(2):540-4. [MEDLINE: 7637373]">Kroshus 1995</a>), but the use of LMWH agents can be complicated by their underlying organ dysfunction, particularly liver and kidney transplant recipients, where major bleeding complications have been reported due to over anticoagulation. Other developing options are new oral anticoagulants, which are currently available as prophylaxis against thromboembolic events, such as venous thromboembolism and pulmonary embolism (PE). These include inhibitors of Factor Xa (apixaban, rivaroxaban) and direct thrombin inhibitors (dabigatran). </p> <p>Antiplatelet agents (aspirin, clopidogrel, dipyridamole) are also often used as prophylaxis against cardiac or cerebrovascular events and can now be monitored in the perioperative period using techniques such as platelet mapping (<a href="./references#CD011557-bbs2-0029" title="KaurJ , JonesN , MallettS . Thrombelastography platelet mapping is a useful preoperative tool in surgical patients taking antiplatelet medication. British Journal of Anaesthesia2009;103(2):304; author reply 304-5. [MEDLINE: 19596760]">Kaur 2009</a>). Newer antiplatelet agents are now available that inhibit cyclooxygenase like aspirin (triflusal), adenosine diphosphate receptors (prasugrel) and glycoprotein IIb/IIIa receptors (tirofiban). These have been pioneered in the arena of coronary artery interventions but may have a role in preventing acute and chronic graft thrombosis. </p> </section> <section id="CD011557-sec-0012"> <h3 class="title" id="CD011557-sec-0012">How the intervention might work</h3> <p>Thrombosis occurs because of a disturbance in normal laminar blood flow, blood composition or endothelial injury (Virchow's triad). Organ transplant recipients appear to be at particular acute risk because of both the vascular endothelial injury consequent on ischaemia‐reperfusion injury and the presence of multiple vascular surgical anastomoses, although in certain situations other risks (e.g. diabetic hypercoagulability), may predominate (<a href="./references#CD011557-bbs2-0035" title="MuthusamyAS , GiangrandePL , FriendPJ . Pancreas allograft thrombosis. Transplantation2010;90(7):705-7. [MEDLINE: 20616765]">Muthusamy 2010</a>). </p> <p>Thromboprophylactic medications work by changing the local environment in the graft from a prothrombotic milieu. However, there is a significant risk of bleeding in patients during the perioperative period. In this respect, monitoring the efficacy of therapy is crucial. For some agents there are standard laboratory tests which can be used to guide dosing (e.g. warfarin and the international normalised ratio, INR); whereas in others, more sophisticated tests such as thromboelastography (antiplatelet agents) may be more appropriate. </p> </section> <section id="CD011557-sec-0013"> <h3 class="title" id="CD011557-sec-0013">Why it is important to do this review</h3> <p>The number of organ transplants continues to grow, and the potential indications for transplantation widen. However, the pool of potential optimal organ donors remains relatively constant and this has forced surgeons to use expanded criteria donors which are at higher risk of thrombosis due to either long periods of ischaemia or donor comorbidity (atherosclerosis). This combination not only leads to a greater potential role for thromboprophylactic therapy but is also reflected in the ageing recipient population afflicted with other vascular morbidities and at greatest risk from bleeding complications. </p> <p>Bleeding in patients on thromboprophylactic therapy is generally managed by haemostatic measures such as reversal of anticoagulation where possible and the judicious use of blood products as required. In severe cases, if bleeding is in the operative field, return to the operating theatre for either thoracotomy (heart, lung) or laparotomy (abdominal) to identify and secure the bleeding vessel is essential. Consequent morbidity (and death) can be high and related to the respiratory and general debilitating effects of further surgery. </p> <p>This review examined the use, monitoring and complications of thromboprophylactic therapy among organ recipients and highlight areas where further research is required. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011557-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011557-sec-0014"></div> <p>This review aimed to look at the benefits and harms of instituting thromboprophylaxis to patients undergoing solid organ transplantation. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011557-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011557-sec-0015"></div> <section id="CD011557-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011557-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) examining the use of interventions to prevent thrombosis in solid organ transplant recipients. </p> </section> <section id="CD011557-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD011557-sec-0019"> <h5 class="title">Inclusion criteria</h5> <p>We included all studies designed to examine interventions to prevent thrombosis in solid organ transplant recipients. In our initial protocol we stated that there would be no upper age limit for recipients, children would be included and patients receiving one or more solid organ transplants (multi visceral) would be included (heart, liver, lung, kidney, and pancreas). </p> </section> <section id="CD011557-sec-0020"> <h5 class="title">Exclusion criteria</h5> <p>Studies must have adequately detailed the thromboprophylactic strategy used to enable comparison of treatments and outcomes. </p> </section> </section> <section id="CD011557-sec-0021"> <h4 class="title">Types of interventions</h4> <p>The thromboprophylactic interventions under consideration included the following.</p> <p> <ol id="CD011557-list-0001"> <li> <p>Anticoagulants: LMWH, UFH, low molecular weight dextran sulphate, heparinoids, direct thrombin inhibitors (including bivalirudin, argatroban and lepirudin), coumarins (including warfarin), factor Xa inhibitors (including fondaparinux). </p> </li> <li> <p>Antiplatelet agents such as aspirin, clopidogrel, dipyridamole.</p> </li> </ol> </p> <p>These were analysed in separate sections as different interventions.</p> <p>We anticipated that studies would potentially use a number of different designs to assess efficacy and complications of different strategies. </p> <p> <ol id="CD011557-list-0002"> <li> <p>Intervention A versus Intervention B</p> </li> <li> <p>Dose of medication administered and variation in dosing</p> </li> <li> <p>Route of administration</p> </li> <li> <p>Frequency of administration of anticoagulant drugs</p> </li> <li> <p>Duration of thromboprophylaxis</p> </li> <li> <p>Measurement of haemostasis and the thromboprophylactic effect</p> </li> <li> <p>Timing and methods undertaken to investigate for evidence of thrombosis.</p> </li> </ol> </p> </section> <section id="CD011557-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>This review focused on the benefits and harms of thromboprophylactic medications in the early peritransplant period (&lt; 90 days post‐transplant) and the outcome measures reflected this, being broadly related to surgical complications. The primary adverse outcomes are the severe ends of the spectrum being graft thrombosis and the incidence of bleeding events. "Softer" end points like blood loss in the postoperative period can be measured by either the output of surgical drains or in laboratory based tests like the haematocrit or haemoglobin concentration. In themselves these outcome measures may not be clinically significant but may portend an adverse patient outcome. Likewise, acute rejection of a transplant can normally be managed with escalation of immunosuppressive therapy and in only a few cases will lead to graft loss and retransplantation ‐ the important clinical outcome. </p> <p>Each type of solid organ transplant (e.g. heart, lung) was considered separately and reported on in a separate subsection against the following outcome measures: </p> <p> <ul id="CD011557-list-0003"> <li> <p>Early graft thrombosis (venous/arterial)</p> </li> <li> <p>Bleeding events</p> </li> <li> <p>Re‐operation or readmission to intensive care</p> </li> <li> <p>Blood transfusion requirements</p> </li> <li> <p>Hospital stay</p> </li> <li> <p>Death (&lt; 90 days post transplant)</p> </li> <li> <p>Idiosyncratic adverse events related to therapy (e.g. acute kidney injury (AKI), haemorrhagic stroke, heparin‐induced thrombocytopenia, peptic ulceration) </p> </li> <li> <p>Graft survival</p> </li> <li> <p>One‐ and five‐year patient survival.</p> </li> </ul> </p> <section id="CD011557-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011557-list-0004"> <li> <p>Early (&lt; 90 days) graft thrombosis</p> </li> <li> <p>Major bleeding events</p> </li> <li> <p>Re‐operation or readmission to intensive care</p> </li> <li> <p>Blood transfusion requirements.</p> </li> </ol> </p> </section> <section id="CD011557-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011557-list-0005"> <li> <p>Hospital stay</p> </li> <li> <p>Death (&lt; 90 days post‐transplant)</p> </li> <li> <p>Idiosyncratic adverse events related to thromboprophylactic therapy (e.g. AKI, haemorrhagic stroke, heparin‐induced thrombocytopenia) </p> </li> <li> <p>Graft survival (long‐term death censored graft survival)</p> </li> <li> <p>Patient survival (one and five‐year)</p> </li> <li> <p>Occurrence of non‐graft thrombosis, such as deep vein thromboses (DVT) and PE.</p> </li> </ol> </p> </section> </section> </section> <section id="CD011557-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011557-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Register of Studies</a> up to 10 November 2020 through contact with the Information Specialist using search terms relevant to this review. The Register contains studies identified from the following sources: </p> <p> <ol id="CD011557-list-0006"> <li> <p>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Searches of kidney and transplant journals, and the proceedings and abstracts from major kidney and transplant conferences </p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney and transplant journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of search strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available on the Cochrane Kidney and Transplant website under <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">CKT Register of Studies</a>. </p> <p>See <a href="./appendices#CD011557-sec-0101">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD011557-sec-0027"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD011557-list-0007"> <li> <p>Reference lists of review articles, relevant studies, and clinical practice guidelines.</p> </li> <li> <p>Contacting relevant individuals/organisations seeking information about unpublished or incomplete studies. </p> </li> </ol> </p> </section> </section> <section id="CD011557-sec-0028"> <h3 class="title" id="CD011557-sec-0028">Data collection and analysis</h3> <section id="CD011557-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that may have been relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable; however studies and reviews that might include relevant data or information on studies would be retained initially. Two authors independently assessed retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria. </p> </section> <section id="CD011557-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently using standard data extraction forms. Studies reported in non‐English language journals would have been translated before assessment. Where more than one publication of one study existed we grouped reports together and the publication with the most complete data was used in the primary analysis with data from subordinate publications included only if this data was not in the primary source. </p> </section> <section id="CD011557-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD011557-bbs2-0025" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>) (see <a href="./appendices#CD011557-sec-0102">Appendix 2</a>). </p> <p> <ul id="CD011557-list-0008"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD011557-list-0009"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors (detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD011557-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes such as thrombosis, bleeding, graft loss, adverse events or death, results were expressed as risk ratio (RR) with 95% confidence intervals (CI). A RR &gt; 1 would indicate a higher rate of events associated with that particular treatment. Where continuous scales of measurement were used to assess the effects of treatment, for example, anti‐Xa levels or INR, the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used. We attempted to analyse graft and patient survival as time to event data using O, E and V statistics. </p> </section> <section id="CD011557-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate including any studies using cluster randomised or cross‐over studies. However, we did anticipate that studies may have randomised individuals to combination therapies (e.g. dual antiplatelet agents) versus either no therapy or an alternate strategy. These issues were possible would have been and have been explored in subgroup analyses and combination comparisons. </p> </section> <section id="CD011557-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>Any further information required from the original author was requested by written correspondence (e.g. emailing corresponding author), however we received no responses from any authors. We planned to evaluate important numerical data such as screened, randomised patients as well as intention‐to‐treat, as‐treated and per‐protocol population; however such data was not present in identified manuscripts. Attrition rates, for example drop‐outs, losses to follow‐up and withdrawals were investigated. Issues of missing data and imputation methods (for example, last‐observation‐carried‐forward) were to be critically appraised (<a href="./references#CD011557-bbs2-0025" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> <p>If the study met the inclusion criteria and considered of adequate quality, we attempted to impute missing data with replacement values, and treated these as if they were observed (e.g. last observation carried forward, imputing an assumed outcome such as assuming all were poor outcomes, imputing the mean, imputing based on predicted values from a regression analysis). For missing standard deviations we imputed from one or more other studies with similar designs, patient groups, and numbers (<a href="./references#CD011557-bbs2-0017" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7-10. [MEDLINE: 16360555]">Furukawa 2006</a>). In all cases of imputed data a sensitivity analysis was performed to assess how sensitive these assumptions were to reasonable changes and variance. </p> </section> <section id="CD011557-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed the heterogeneity by visual inspection of the forest plot. We then quantified statistical heterogeneity using the I² statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<a href="./references#CD011557-bbs2-0024" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [MEDLINE: 12958120]">Higgins 2003</a>). A guide to the interpretation of I² values is as follows. </p> <p> <ul id="CD011557-list-0010"> <li> <p>0% to 40%: might not be important</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>The importance of the observed value of I² depends on the magnitude and direction of treatment effects and the strength of evidence for heterogeneity (e.g. P‐value from the Chi² test, or a 95% CI for I²) (<a href="./references#CD011557-bbs2-0025" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD011557-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to use funnel plots to assess for the potential existence of small study bias, however insufficient studies were available (<a href="./references#CD011557-bbs2-0025" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD011557-sec-0037"> <h4 class="title">Data synthesis</h4> <p>Data was pooled using the random‐effects model, but we also performed fixed‐effect models to ensure robustness of the model chosen and susceptibility to outliers. If possible or applicable we explored the effects of treatment using expressions of absolute effects of treatment (numbers needed to treat). </p> </section> <section id="CD011557-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was to be used to explore possible sources of heterogeneity for example type of solid organ transplanted and study quality. Heterogeneity among participants could be related to age, gender, comorbidities and underlying diseased organ pathology. Heterogeneity in treatments could be related to prior agent(s) used and the agent, dose, and duration of therapy (dual antiplatelet agents versus single agent). Adverse effects were assessed separately for each intervention, as they are likely to be different for the various agents used. Where possible, the risk difference with 95% CI was calculated for each adverse effect, either compared to no treatment or to another agent. We planned to perform the following subgroup analyses, but there was insufficient data: </p> <p> <ul id="CD011557-list-0011"> <li> <p>High risk (pancreas transplants, donor comorbidity) versus low risk (standard donor criteria) </p> </li> <li> <p>High intensity (heparins/anti‐Xa) versus low intensity (colloids and antiplatelet therapy). </p> </li> </ul> </p> </section> <section id="CD011557-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis using a fixed‐effects model, as well as a random‐effects model. The following sensitivity analyses were planned but could not be performed due to lack of studies. </p> <p> <ul id="CD011557-list-0012"> <li> <p>Repeating the analysis excluding unpublished studies</p> </li> <li> <p>Repeating the analysis taking account of risk of bias, as specified</p> </li> <li> <p>Repeating the analysis excluding any very long or large studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding any small studies to establish how much they dominate the results </p> </li> <li> <p>Repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), and country. </p> </li> </ul> </p> </section> <section id="CD011557-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD011557-bbs2-0039" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD011557-bbs2-0019" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD011557-bbs2-0020" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD011557-bbs2-0040" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Schunemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p>Outcomes presented in 'Summary of findings' tables were the following.</p> <p> <ul id="CD011557-list-0013"> <li> <p>Early graft thrombosis (venous/arterial)</p> </li> <li> <p>Major bleeding events: UFH</p> </li> <li> <p>Major bleeding events: any heparin (including fractionated heparin)</p> </li> <li> <p>Readmission to intensive care: all heparin</p> </li> <li> <p>Blood transfusion requirements</p> </li> <li> <p>Graft and patient survival</p> </li> <li> <p>Non‐graft thrombosis.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011557-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011557-sec-0041"></div> <section id="CD011557-sec-0042"> <h3 class="title">Description of studies</h3> <p>See the <a href="./references#CD011557-sec-0112" title="">Characteristics of included studies</a> and <a href="./references#CD011557-sec-0113" title="">Characteristics of excluded studies</a>. </p> <section id="CD011557-sec-0043"> <h4 class="title">Results of the search</h4> <p>We searched the Specialised Register, MEDLINE, EMBASE, and CENTRAL and identified 16 reports. One additional study was identified in the reference section of one report. After screening titles and abstracts two non‐RCTs were excluded. We then screened the full‐text reports; nine studies (11 reports) were included, and one study (three reports) was excluded (see <a href="#CD011557-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011557-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011557-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011557-sec-0044"> <h4 class="title">Included studies</h4> <p>Most of the studies included in this review were not aimed primarily at investigating early graft thrombosis and only two of the kidney transplantation studies (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>) report on early graft thromboses. </p> <section id="CD011557-sec-0045"> <h5 class="title">Kidney transplantation</h5> <p>A total of 544 kidney transplant recipients from seven studies (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>; <a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>; <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>) were included in this review; full details of each study can be found in the "Characteristics of Included Studies" section. </p> <p><a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> and <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> looked at patients who were already experiencing an acute rejection episode and reported on levels of platelet activation, graft recovery time, and rates of patient and graft survival. </p> <p><a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> looked at the type of anticoagulant used in pre‐transplant dialysis on graft function, graft survival and bleeding events. </p> <p><a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a> and <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> both note in their introductory paragraphs that intravascular coagulation is often seen in rejected grafts and that manipulation of coagulation systems may affect outcomes (such as graft function) but neither study set out to explicitly investigate rates of graft thrombosis in their patients. <a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a> was particularly interested in the role of heparin in improving post‐operative graft function and also reported on rates of haemorrhagic complications, and graft survival. <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> was “spurred by internal and external pressures for cost containment” and primarily aimed to compare aspirin to dipyridamole as part of the routine care of patients post transplant. <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> reported on graft function, rates of gastrointestinal haemorrhage, and transfusion requirements. </p> <p><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> and <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> were the only studies that mentioned investigating rates of thrombosis as a main aim of their study. However, both looked at very particular groups of kidney transplant recipients; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> was interested in patients receiving cyclosporin A as immunosuppression and the role of heparinisation in this group. <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> aimed to investigate the role of routine heparinisation in “non‐risky” kidney transplant recipients.  </p> <p>Only four studies investigated ongoing anti‐thrombosis strategies which were started at the time of kidney transplantation, and all but one were completed over 30 years ago (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). As such, these studies were conducted in an environment that was very different to that of modern transplantation where certain variables such as cold ischaemic times, preservation methods, and immunosuppressive protocols were different to those used today. </p> <p>Studies were conducted in China (<a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>), Australia (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>), UK (<a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>), USA (<a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>), Egypt (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>), and Austria (<a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a>). </p> <p>One study was performed in live donor transplants (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>), one in grafts donated following brain death (<a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a>), and one in grafts donated following circulatory death (<a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>). The remaining four studies (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>; <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>) all specify looking at patients who had received deceased donor donations and we have inferred from the timing of these studies that they likely donated following brainstem death. </p> <p>Heparin was the most commonly studied thromboprophylactic therapy, being the intervention in six of the seven studies. Three studies examined unfractionated subcutaneous heparin (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>), two investigated a combination of heparin and Lipo‐PGE<sub>1</sub> (<a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>), and one examined LMWH (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>). <a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> was conducted slightly differently as their intervention was the type of anticoagulant used in pre‐transplant dialysis. (see <a href="./references#CD011557-sec-0112" title="">Characteristics of included studies</a>). </p> <p>Four of the seven studies reviewed their intervention in all patients post kidney transplantation (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>) while the remaining three studies only looked at patients experiencing an acute rejection episode (<a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>; <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>). </p> <p>Six studies (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>; <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>) compared their intervention to a control group, although in three studies (<a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>; <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>) it was not clear whether the control group received a placebo. Only <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> compared the use of aspirin to dipyridamole without the use of a placebo or no treatment. </p> </section> <section id="CD011557-sec-0046"> <h5 class="title">Liver transplantation</h5> <p>Two studies (<a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a>; <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a>) (168 patients) investigated interventions to prevent thrombosis in liver transplantation. Both were conference abstracts and no full publications of either study were available at the time of writing this review. As full manuscripts were not available it was often difficult to elicit full details about study methods and outcome reporting due to lack of available information. We contacted authors of both studies to request further information, but we received no response. </p> <p>Both studies stated using "randomised methodology", however further details about their randomisation methods were unavailable. Neither study mentioned blinding or use of a placebo. Similarly it was not mentioned in either study what type of donor the organs were retrieved from. </p> <p><a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> was an Iranian study of 139 patients undergoing orthotopic liver transplantation who had a portal vein thrombosis immediately prior to transplantation. Following thrombectomy, initiation of heparin therapy and confirmation of portal vein patency by Doppler study, patients were randomised to receive either aspirin or warfarin therapy for three months. Patients with Budd‐Chiari and those where thrombectomy was not possible were excluded. Their study was mainly aimed at investigating rates of rethrombosis in these patients.  </p> <p><a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> looked at 29 patients undergoing orthotopic liver transplantation in Argentina who had high levels of anti‐phospholipid antibodies or lupus anticoagulant and were also assessed to be at “high risk of thrombosis” (factors used to determine 'high risk' were not described). These patients were randomised to receive either low dose aspirin with or without LMWH post‐transplantation or pre‐operative plasmapheresis followed by postoperative anticoagulation for three months with the aim of investigating differences in postoperative thrombotic complications. </p> <p>Both studies reported specifically on rates of thrombotic complications. <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> reported on the rates of death and graft loss in their patients. <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> only reported on patients who died due to haemorrhagic complications. The number of patients who died from other causes and the number of non‐lethal haemorrhagic complications were not mentioned in the conference abstract. </p> </section> <section id="CD011557-sec-0047"> <h5 class="title">Non‐liver, non‐kidney solid organ transplantation</h5> <p>No RCTs were identified that reviewed thromboprophylaxis (anticoagulant or antiplatelet) therapies in recipients of heart, lung, pancreas, bowel, or any other solid organ transplantation. The remainder of this review will focus solely on studies pertaining to liver or kidney transplantation. </p> </section> </section> <section id="CD011557-sec-0048"> <h4 class="title">Excluded studies</h4> <p>One study was excluded following full text review (see <a href="./references#CD011557-sec-0113" title="">Characteristics of excluded studies</a>). <a href="./references#CD011557-bbs2-0010" title="ZhangY , GuanD , XiaC . The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function [abstract]. In: XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL. 2002. [CENTRAL: CN-00417006] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the transplanted kidney function [Erratum in: Transplant Proc. 2003 Aug;35(5):2060 Note: Zhang YG [corrected to Zhang Y]; Guan D [corrected to Guan D L]]. Transplantation Proceedings2003;35(4):1360-3. [MEDLINE: 12826159]ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]2003;41(12):881-4. [MEDLINE: 14728824]">Zhang 2003a</a>, did not adequately detail their thromboprophylactic strategy. Only a small subsection of <a href="./references#CD011557-bbs2-0010" title="ZhangY , GuanD , XiaC . The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function [abstract]. In: XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL. 2002. [CENTRAL: CN-00417006] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Relationship between the expression levels of CD61, CD63, and PAC-1 on platelet surface in peripheral blood and the transplanted kidney function [Erratum in: Transplant Proc. 2003 Aug;35(5):2060 Note: Zhang YG [corrected to Zhang Y]; Guan D [corrected to Guan D L]]. Transplantation Proceedings2003;35(4):1360-3. [MEDLINE: 12826159]ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. The relationship between the peripheral blood of CD61, CD63, PAC-1 and the transplant kidney function. Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]2003;41(12):881-4. [MEDLINE: 14728824]">Zhang 2003a</a> was relevant to our review. They primarily set out to investigate the relationship between markers of platelet activation and the incidence of tubular necrosis and rejection episodes in kidney transplant recipients. Thirty of their patients who experienced acute rejection episodes were randomised into a control arm or treatment with anticoagulation; however the only detail given about what the patients in the treatment arm received was: “anticoagulants including Lipo‐PGE<sub>1</sub>, Dashen, or low dosage heparin” with no detail given on dose, frequency or duration of therapy and no breakdown given of how many patients received each of the anticoagulants specified.  </p> </section> </section> <section id="CD011557-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary of the risk of bias in included studies can be found in <a href="#CD011557-fig-0002">Figure 2</a> and <a href="#CD011557-fig-0003">Figure 3</a>. Some methodology details were absent from earlier studies which made it difficult to assess the risk of bias, particularly regarding use of placebo and method of randomisation. No study made specific reference to the use of intention‐to‐treat analysis. </p> <div class="figure" id="CD011557-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011557-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011557-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011557-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011557-sec-0050"> <h4 class="title">Allocation</h4> <section id="CD011557-sec-0051"> <h5 class="title">Kidney transplantation</h5> <p>Two studies (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>) did not discuss their methods of random sequence generation or allocation concealment and so it was unclear to what extent their methods introduced selection bias.  </p> <p><a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> reported on patients undergoing acute rejection episodes confirmed by needle biopsy. Their methods of randomisation were not well described, but as they stated that patients were randomised based on biopsy results this was deemed to be at high risk of bias.  </p> <p><a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> used a randomisation method that was deemed to be at low risk of bias. They described using sealed opaque envelopes that were kept in the operating theatres and were only opened once the patient was enrolled. </p> <p><a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> and <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> both used patients hospital numbers to randomise their patients and were therefore judged to be at high risk of bias (quasi‐RCT) as clinicians would have known which group the patient would have been entered into prior to enrolment.  </p> <p><a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> used a paired design to their study where patients were initially divided into two groups based on serum potassium levels. Each of those groups were then randomised using a blind envelope technique into treatment and control arms. As the initial division was based on laboratory values, this was assessed to be at high risk of selection bias, however as the remainder of their randomisation methods were low risk, we deemed it unlikely that this would have had a major impact on the quality of evidence. </p> </section> <section id="CD011557-sec-0052"> <h5 class="title">Liver transplantation</h5> <p>Both <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> and <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> stated that their patients were randomly placed into the two treatment groups, however their methods of randomisation were not described. As such, it was difficult to assess the potential degree of bias. However, <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> had two treatment groups, one with 12 patients and one with 17 patients which raised suspicions about their randomisation methods and consequently we assessed this study to be at high risk of bias. <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> seems to have included patients with portal vein thrombosis at the time of transplantation and were started on heparin therapy subsequently. These patients were then only included in the study if Doppler ultrasound studies confirmed portal vein patency. We believed this study to be at high risk of selection bias, as this decision relied on a significant degree of subjective operator assessment. </p> </section> </section> <section id="CD011557-sec-0053"> <h4 class="title">Blinding</h4> <section id="CD011557-sec-0054"> <h5 class="title">Kidney transplantation</h5> <p><a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a> and <a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a>, described adequate double blinding methods and were deemed to be at low risk of bias. </p> <p><a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> and <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> were single blind studies where the assessors were not blinded to the outcomes. However, as the only outcome relevant to this review was patient survival, lack of blinding was unlikely to bias this outcome so these studies were deemed to be at low risk of bias. </p> <p><a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> used a single blind methodology, however one of the outcomes that they were investigating was transfusion requirements and it was certainly possible for the treating physician to be aware of the treatment allocation and influence the decision to transfuse. We judged this study to be at high risk of bias. </p> <p><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> appears to be an unblinded study, although details of specific methodology were lacking from the text. The authors did report on a number of thromboembolic events including renal vein thrombosis however, it was not mentioned whether renal vein thrombus was partial or complete, or whether there were any differences in the number of scans performed in the different groups. Due to lack of blinding, surgeons were likely to have a lower threshold to perform Doppler US in those not receiving heparin than those receiving heparin. We judged this study to be at high risk of detection bias. </p> <p><a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> was unblinded and we had concerns about their methods of patient selection. As such, this study was judged at being at high risk of bias. </p> </section> <section id="CD011557-sec-0055"> <h5 class="title">Liver transplantation</h5> <p>Neither <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> nor <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> specifically mentioned blinding in their conference abstract and it is unclear to what extent, if any, that blinding was used. Both studies reported on death and thrombotic complications and while it is very unlikely that lack of blinding would not have influenced mortality reporting, it is certainly possible that lack of blinding may have affected the clinicians' threshold for investigating for a thrombosis. In essence, if a clinician knew a patient was receiving a particular therapy, they may have been more or less assiduous in requesting investigations to evaluate the graft vasculature.  </p> <p>Neither study described their criteria for investigating thrombotic complications in detail, with <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> simply stating: “clinical and Doppler USS evaluations were performed immediately postoperatively and at different time points for the first 6 months.” Furthermore, <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> neither predefined what they considered to be a thromboembolic event nor what threshold of severity was used. </p> <p>Although the information was limited, we deemed it likely that blinding was not used to a sufficient level to prevent the introduction of performance bias and therefore judged these studies as being at high risk of bias. </p> </section> </section> <section id="CD011557-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>There were no concerns about any of the included studies being at high risk of attrition bias. </p> </section> <section id="CD011557-sec-0057"> <h4 class="title">Selective reporting</h4> <section id="CD011557-sec-0058"> <h5 class="title">Kidney transplantation</h5> <p>There were no concerns about any of the included studies being at high risk of selective reporting. </p> </section> <section id="CD011557-sec-0059"> <h5 class="title">Liver transplantation</h5> <p><a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> reported on death due to haemorrhagic complication; however, they do not report on death from other outcomes or other haemorrhagic complications. This raised concerns that this study may have been at high risk of reporting bias. However, as all our assessors had available to them was the conference abstract, it was concluded that there was insufficient information available to permit judgement.  </p> </section> </section> <section id="CD011557-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <section id="CD011557-sec-0061"> <h5 class="title">Kidney Transplantation</h5> <p><a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> excluded 45 “risky” patients for a number of reasons including young age, extent of atherosclerotic disease, history of thromboembolic phenomena, and intraoperative technical difficulty. However, none of these exclusion criteria seemed to be predefined and it appears to be down to the surgeon's discretion as to which patients were deemed “risky”. For these reasons, we judged this study to be at high risk of inclusion bias. </p> <p>There were no other potential sources of bias identified across the remainder of the included studies. </p> </section> <section id="CD011557-sec-0062"> <h5 class="title">Liver Transplantation</h5> <p><a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> stated that they included patients at “high thrombotic risk” however, there was no further detail given on how this decision was made. As such, we judged this study to be at potentially high risk of inclusion bias.  </p> </section> </section> </section> <section id="CD011557-sec-0063"> <h3 class="title" id="CD011557-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD011557-tbl-0001"><b>Summary of findings 1</b> Heparin versus placebo for preventing thrombosis in kidney transplant recipients</a> </p> <section id="CD011557-sec-0064"> <h4 class="title">Kidney transplantation</h4> <section id="CD011557-sec-0065"> <h5 class="title">Anticoagulants versus placebo</h5> <p>Three studies compared heparin (unfractionated or low molecular weight) to placebo (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). </p> <p> <ul id="CD011557-list-0014"> <li> <p><a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>: 18 patients were each administered 2500 U of subcutaneous heparin pre‐operatively and continued at 2500 U every 12 hours for 17 days </p> </li> <li> <p><a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>: three‐armed study; 25 patients received 5000 IU of UFH twice daily for 1 week, 25 received a dose of prophylactic subcutaneous LMWH (tinzaparin sodium, once daily 3500 anti‐Xa IU for 1 week post‐operatively), and 25 received no heparin. </p> </li> <li> <p><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>: 32 patients received 5000 IU of subcutaneous heparin twice daily for 7 days or until the patient became fully mobile.  </p> </li> </ul> </p> <section id="CD011557-sec-0066"> <h6 class="title">Early graft thrombosis (venous/arterial)</h6> <p>Two studies reported this outcome (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>) (144 participants). </p> <p> <ul id="CD011557-list-0015"> <li> <p><a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> reported no early graft thromboses in either the UFH group, prophylactic LMWH group, or control group (no heparinisation). </p> </li> <li> <p><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> reported that the effect of heparin compared to placebo on early graft thrombosis was uncertain. There were two graft vein thromboses in the placebo group, and no early graft thromboses in the subcutaneous heparin group (P = 0.495). This study only randomised 69 participants so statistical power was limited and there was also high risk of bias in several domains (random sequence generation bias, allocation concealment bias, performance bias, detection bias, reporting bias). </p> </li> </ul> </p> </section> <section id="CD011557-sec-0067"> <h6 class="title">Major bleeding events</h6> <p>Three studies reported this outcome (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> studied both UFH and LMWH (tinzaparin sodium). <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> could contribute no data to the meta‐analysis as there were no bleeding events in either the UFH group or the control group. </p> <p>UFH may make little or no difference versus placebo to the rate of major bleeding events (<a href="./references#CD011557-fig-0004" title="">Analysis 1.1</a> (3 studies, 155 participants): RR 2.92, 95% CI 0.89 to 9.56; I² = 0%; low certainty evidence). This corresponds to an absolute risk increase of 0.09 (95% CI ‐0.07 to 0.26). There was high risk of bias in several domains in <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> (including random sequence generation, allocation concealment, performance, detection, and reporting). </p> <p>A separate analysis was performed comparing any heparin (unfractionated or LMWH) to control (no heparin). Heparin may make little or no difference versus control to the number of major bleeding events (<a href="./references#CD011557-fig-0005" title="">Analysis 1.2</a> (3 studies, 180 participants): RR 2.70, 95% CI 0.89 to 8.19; I² = 0%; low certainty evidence). This corresponds to an absolute risk increase of 0.10 (95% CI ‐0.05 to 0.24). There is high risk of bias in several domains in <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>, and <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> has high risk of performance bias and inclusion bias. LMWH was only used in <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> and the risk of bleeding with its use therefore remains unclear. </p> <p>We performed sensitivity analyses, where we repeated the above analyses using a fixed‐effect rather than random effects model. Using this fixed‐effect model, UFH may increase the risk of haemorrhagic events compared to placebo (RR 3.33, 95% CI 1.04 to 10.67, P = 0.04). The effect of LMWH remains unclear (very low certainty evidence). Due to small numbers of studies, funnel plots were not generated. </p> </section> <section id="CD011557-sec-0068"> <h6 class="title">Readmissions to intensive care</h6> <p>Three studies reported this outcome (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). </p> <p>It is uncertain whether heparin decreases the risk of readmission to intensive care (<a href="./references#CD011557-fig-0006" title="">Analysis 1.3</a> (3 studies, 180 participants): RR 0.68, 95% CI 0.12 to 3.90; I² = 45%; very low certainty evidence). The individual studies varied in effect size and direction. I² was 45%, suggesting there may be moderate heterogeneity present between the studies. The I² did not reach significance (P = 0.16) but is likely underpowered given the low number of studies which all had small sample sizes. The confidence intervals in this meta‐analysis are large and interpretations should be cautious. </p> </section> <section id="CD011557-sec-0069"> <h6 class="title">Blood transfusion requirements</h6> <p>One study reported this outcome (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>). </p> <p>They reported an unclear effect of any heparin, compared with control on blood transfusions (P = 0.56) or mean number of transfused units (P = 0.69) (very low certainty evidence). In the placebo group, there were eight blood transfusions (mean transfused units 0.5 ± 0.8). In the LMWH group, there were eleven blood transfusions (mean transfused units 0.6 ± 0.8). In the UFH group, there were twelve blood transfusions (mean transfused units 0.6 ± 0.7). This evidence is very low certainty as it comes from a single small study (75 patients), at high risk of performance and inclusion bias. </p> </section> <section id="CD011557-sec-0070"> <h6 class="title">Death (&lt; 90 days post transplant)</h6> <p>One study reported this outcome (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>). </p> <p><a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a> indicated an unclear effect of heparin compared with control on death (P = 1.000). One patient died in each of the heparin (cerebral haemorrhage) and placebo (myocardial infarction) groups. There is an unclear risk of random sequence generation bias and allocation concealment bias in this study. </p> </section> <section id="CD011557-sec-0071"> <h6 class="title">Non‐graft thrombosis</h6> <p>Two studies reported this outcome (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). </p> <p>It is uncertain whether heparin reduces the occurrence of non‐graft thrombosis (very low certainty). </p> <p> <ul id="CD011557-list-0016"> <li> <p><a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> reported no DVT or PE in any group. Spontaneous closure of arteriovenous fistulae occurred in one patient in the control group, one patient in the LMWH group and two participants in the UFH group (P = 0.79). </p> </li> <li> <p><a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> reported little difference to the incidence of non‐graft thromboses (P = 0.118) or thromboembolic complications (P &gt; 0.05); very low certainty evidence. There were no non‐graft thromboses in the 32 patients receiving heparin. Four of the 37 patients in the control group experienced a non‐graft thrombosis (three arterio‐venous fistula thromboses, and one PE from a DVT). Of note, <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a> combined graft thromboses and non‐graft thromboses into a single outcome of "thromboembolic complications". There were no thromboembolic complications in the heparin group, and six complications in five participants in the control group (P &gt; 0.05). The severity of thromboembolic events was not mentioned and authors did not pre‐define what will count as a thromboembolic event. </p> </li> </ul> </p> </section> <section id="CD011557-sec-0072"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported for the comparison anticoagulants versus placebo: hospital stay, idiosyncratic adverse events related to therapy, graft survival, or patient survival </p> </section> </section> <section id="CD011557-sec-0073"> <h5 class="title">Antiplatelet interventions</h5> <p><a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>, <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> and <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> studied antiplatelet interventions. </p> <p> <ul id="CD011557-list-0017"> <li> <p><a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a> compared buffered aspirin and dipyridamole following deceased donor kidney transplantation. Patients randomised to the aspirin group received buffered aspirin (5 mg twice/day). The dipyridamole group received dipyridamole (100 mg 4 times/day). </p> </li> <li> <p><a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> and <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> included only patients experiencing acute rejection and randomised into a group receiving lipo‐PGE<sub>1</sub> plus low dose heparin and a "control" group. The aim of these studies was to investigate the impact of platelet aggregation on acute rejection, not to investigate graft thrombosis. </p> <ul id="CD011557-list-0018"> <li> <p>In <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>, patients with confirmed acute rejection episodes following renal transplantation were randomly assigned Lipo PGE<sub>1</sub> (plus low dose heparin) therapy or a control group. In the intervention group, 20 μg/day of Lipo PGE<sub>1</sub> and 5 mg/day of heparin were administered for 2 weeks if no bleeding was present. </p> </li> <li> <p>In <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>, the intervention group received Lipo‐PGE<sub>1</sub> (20 μg/day) and heparin (10 mg/day), administered until reversal of rejection if no bleeding was present. </p> </li> </ul> </li> </ul> </p> <section id="CD011557-sec-0074"> <h6 class="title">Major bleeding events</h6> <p>One study reported this outcome (<a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>). </p> <p>There is currently insufficient evidence to indicate an effect of buffered aspirin compared with dipyridamole on the risk of bleeding events (very low certainty evidence). In <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>, there were seven gastrointestinal haemorrhagic events in the buffered aspirin group whereas there were no gastrointestinal haemorrhagic events in the dipyridamole group (P &lt; 0.01). Though the size of the effect was significant in this study, only 42 participants were included and there was a high risk of bias in several domains, including random sequence generation bias, allocation concealment bias, performance bias, and detection bias. In addition, no mention was made of the ages of participants in each group, and the method of diagnosis of gastrointestinal haemorraghic events was not pre‐defined in this study. Interpretations from results in this study should be cautious. </p> </section> <section id="CD011557-sec-0075"> <h6 class="title">Readmissions to intensive care</h6> <p>One study reported this outcome (<a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>). </p> <p>Buffered aspirin compared to dipyridamole may increase readmissions to intensive care (very low certainty evidence). There were seven readmissions to intensive care in the buffered aspirin group and no readmission to intensive care in the dipyridamole group (P &lt; 0.01). There was a high risk of bias in several domains, including random sequence generation bias, allocation concealment bias, performance bias and detection bias. As the information on this outcome is only available from one small study of 42 participants, there is currently insufficient evidence to indicate an effect of buffered aspirin compared with dipyridamole on the risk of readmission to intensive care. </p> </section> <section id="CD011557-sec-0076"> <h6 class="title">Blood transfusion requirements</h6> <p>One study reported this outcome (<a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>). </p> <p>Buffered aspirin compared to dipyridamole may increase blood transfusion requirements. Five patients required blood transfusions in the buffered aspirin group whereas no blood transfusions occurred in the dipyridamole group (P = 0.018; Fisher's exact test). There was a high risk of bias in several domains, including random sequence generation bias, allocation concealment bias, performance bias and detection bias. As the information on this outcome is only available from one small study of 42 participants, there is currently insufficient evidence to indicate an effect of buffered aspirin compared with dipyridamole on blood transfusion requirements (very low certainty evidence). </p> </section> <section id="CD011557-sec-0077"> <h6 class="title">Death (&lt; 90 days post transplant)</h6> <p>One study reported this outcome (<a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>). </p> <p>There is currently insufficient data to indicate an effect of Lipo PGE<sub>1</sub> plus low dose heparin, compared with control, in terms of effects on mortality (very low certainty evidence). Three patients died in the control group (two due to myocardial infarction, one because of heart failure). One patient died in the treatment group because of heart failure (P = 0.605). The information on this outcome is only available from one small study of 40 participants where there was a high risk of random sequence generation bias. </p> </section> <section id="CD011557-sec-0078"> <h6 class="title">Graft survival</h6> <p>Two studies reported this outcome (<a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>). </p> <p>It remains uncertain whether Lipo PGE<sub>1</sub> plus heparin therapy improves graft survival rates compared to control (very low certainty evidence). The two studies did not explicitly define the start and end points of the survival period, so it is unclear whether they measured survival from the point of randomisation or from the point of transplant. They also did not give any information on whether methods of censoring were used. </p> <p> <ul id="CD011557-list-0019"> <li> <p><a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> (40 participants): one‐year graft survival was 90% and 80% in the intervention and control groups respectively (P &gt; 0.05) </p> </li> <li> <p><a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> (62 participants): one‐year graft survival was 86.7% and 80% in Lipo PGE<sub>1</sub> and control groups respectively (P &gt; 0.05), and the three‐year graft survival rate in Lipo PGE<sub>1</sub> group was 80% whereas in the control group it was 73.3% (P &gt; 0.05). </p> </li> </ul> </p> <p>In <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> there was a high risk of random sequence generation bias and allocation bias, and in <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> there was unclear risk of random sequence generation bias and allocation concealment bias. </p> </section> <section id="CD011557-sec-0079"> <h6 class="title">Patient survival</h6> <p>Two studies reported this outcome (<a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>). </p> <p>Overall there is insufficient evidence as to whether Lipo PGE<sub>1</sub> plus heparin therapy improves patient survival rates compared to control (very low certainty evidence). The two studies did not explicitly define the start and end points of the survival period, so it is unclear whether they measured survival from the point of randomisation or from the point of transplant. They also did not give any information on whether methods of censoring were used. </p> <p> <ul id="CD011557-list-0020"> <li> <p><a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> (40 participants): one‐year patient survival was 95% and 85% in the intervention and control groups respectively (P &gt; 0.05) </p> </li> <li> <p><a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> (62 participants): one‐year patient survival was 93.3% and 86.7% in Lipo PGE<sub>1</sub> and control groups respectively (P &gt; 0.05), and the three‐year patient survival rate in Lipo PGE<sub>1</sub> group was 86.7% whereas in the control group it was 80.0% (P &gt; 0.05). </p> </li> </ul> </p> </section> <section id="CD011557-sec-0080"> <h6 class="title">Other outcomes</h6> <p>The following outcomes were not reported for the comparison for antiplatelet interventions: early graft thrombosis (venous/arterial), hospital stay, idiosyncratic adverse events related to therapy, or non‐graft thrombosis. </p> </section> </section> <section id="CD011557-sec-0081"> <h5 class="title">Anticoagulant during pre‐transplant dialysis</h5> <p><a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> was the only study which aimed to assess the impact of pre‐operative haemodialysis. One of the two sub‐studies in <a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> studied anticoagulation in pre‐transplant haemodialysis. One group (66 patients) received heparin (1000 U/hour) and the control group (44 participants) received trisodium citrate (25 to 50 mmol/hour via arterial line). The study did not include early‐graft thromboses or non‐graft thromboses as an outcome, so the relative thromboprophylactic efficacies of heparin and citrate dialysis are very unclear. This study had a high risk of random sequence generation bias, as allocation was based on tests (pretransplant levels of serum potassium). </p> <p><a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> reported that citrate dialysis may make little or no difference versus heparin dialysis to the rate of bleeding complications (P = 0.56), the one‐year death‐censored graft survival rates (P = 0.44), delayed graft function (P = 0.28), or cellular rejection (P = 0.29) (very low certainty evidence). Seven bleeding complications occurred post‐transplant in each group. One‐year death‐censored graft survival rates were 88% in heparin group and 90% in citrate group respectively (P = 0.44). The study reported five cases of early C4d‐positive graft dysfunction in the heparin group, but there were none in the citrate group (P = 0.08). </p> <p>Hospital stay, death, blood transfusion requirements, readmissions to intensive care, and patient survival rates were not reported. Overall, there is insufficient evidence to assess the impact of heparin and citrate anticoagulation in preoperative haemodialysis (very low certainty). </p> </section> </section> <section id="CD011557-sec-0082"> <h4 class="title">Liver transplantation</h4> <section id="CD011557-sec-0083"> <h5 class="title">Aspirin versus warfarin</h5> <p><a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> (139 patients) compared the risk of portal vein rethrombosis in patients receiving aspirin with patients receiving warfarin post liver transplantation. They focused only on patients with pre‐existing portal vein thrombosis (9.6% of screened patients). Portal vein rethrombosis did not occur in either group. There were two deaths in the warfarin group due to bleeding complications (one with intracranial haemorrhage and one with internal bleeding) and none in the aspirin group. The abstract did not mention the number of patients in each group so no statistical comparisons can be made. </p> <p>The rate of major bleeding complications, hospital stay, blood transfusion requirements, readmissions to intensive care, patient and graft survival rates were not reported. <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> had a high risk of random sequence generation bias and detection bias, with unclear bias in most other domains. Overall, there is insufficient evidence to compare the impact of aspirin and warfarin therapy post liver transplantation (very low certainty). </p> </section> <section id="CD011557-sec-0084"> <h5 class="title">Pre‐transplant plasmapheresis plus post‐transplant anticoagulation versus post‐transplant aspirin ± LMWH </h5> <p><a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> (29 patients) compared the impact of pre‐transplant plasmapheresis plus post‐transplant anticoagulation therapy versus postoperative standard low dose aspirin ± LMWH therapy. They looked exclusively at patients with antiphospholipid antibodies or positive lupus anticoagulant who they additionally deemed to be at high risk of thrombotic complications (no definition of high risk was given); 9.0% of screened patients. The study did not describe which anticoagulation therapy was used in the plasmapheresis arm and it was also unclear the dose of LMWH in the control arm. </p> <p><a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> reported that pre‐transplant plasmapheresis plus post‐transplant anticoagulation therapy may reduce the rate of "thrombotic complications" (not defined).Thrombotic complication rates were 37.9% in aspirin ± LMWH group and 10.3% in plasmapheresis group, respectively (P &lt; 0.0001). They report 3/17 patients in the plasmapheresis group developing antiphospholipid associated complications (catastrophic antiphospholipid syndrome (2), and hepatic artery thrombosis (1)) compared to 11/12 patients in the aspirin ± LMWH group (cerebrovascular ischaemia (3), humeral thrombosis (2), hepatic artery thrombosis (1), intestinal ischaemia (1), retinal artery thrombosis (1), portal vein thrombosis, catastrophic antiphospholipid syndrome (4)). Comparison of early graft thrombosis could not be completed as the number of portal vein thromboses in the plasmapheresis group was not given. This study had high performance bias and high detection bias; "thrombotic complications" was not defined. The number of scans performed in the different groups is not mentioned and the method of randomisation is not described. </p> <p>The study reported that pre‐transplant plasmapheresis plus post‐transplant anticoagulation therapy may make little or no difference to graft survival (P = 0.41) or death (P = 0.09). Graft survival was 91.7% in the aspirin ± LMWH group and 100% in the plasmapheresis group. There was no difference in the development of catastrophic antiphospholipid syndrome between groups. There were more deaths in the aspirin ± LMWH group than the plasmapheresis group (5 and 2 respectively). </p> <p>Hospital stay, bleeding events, blood transfusion requirements, and readmissions to intensive care were not reported. Overall, there is insufficient evidence to compare plasmapheresis plus anticoagulation with aspirin ± LMWH therapy in patients at high risk of thrombosis plus antiphospholipid antibodies or positive lupus anticoagulant (very low certainty). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011557-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011557-sec-0085"></div> <section id="CD011557-sec-0086"> <h3 class="title" id="CD011557-sec-0086">Summary of main results</h3> <section id="CD011557-sec-0087"> <h4 class="title">Kidney transplantation</h4> <p>Overall there is a paucity of evidence from RCTs to guide the use of anticoagulants or antiplatelets in kidney transplant recipients. Only two RCTs comparing anticoagulant strategies in kidney transplantation reported on rate of graft vessel thrombosis (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). In one of these there were no thromboses in either group, so this study offered no evidence on the effect of anticoagulants on rate of graft vessel thrombosis (<a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>). No studies comparing antiplatelets in kidney transplantation reported graft vessel thrombosis. </p> <p>Three studies investigated the use of heparin in kidney transplant recipients (<a href="./references#CD011557-bbs2-0001" title="HorvathJS , TillerDJ , DugginGG , McGrathBP , MontenegroR , JohnsonJR . Low dose heparin and early kidney transplant function. Australian &amp; New Zealand Journal of Medicine1975;5(6):537-9. [MEDLINE: 779750]">Horvath 1975</a>; <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a>; <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>). It remains unclear whether heparin decreases the risk of early graft thrombosis (very low certainty evidence). The evidence is uncertain because only one small study (<a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>) contributes data. The study had only 69 participants so statistical power is limited. Also, there is high risk of bias in several domains in <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>, including random sequence generation bias, allocation concealment bias, performance bias, detection bias, and reporting bias. </p> <p>UFH may make little or no difference versus placebo to major bleeding events (RR 2.92, 95% CI 0.89 to 9.56, I² = 0%; low certainty evidence). The certainty of this evidence is low because only two small studies have been used to make comparisons of bleeding event frequency in heparin and placebo groups. There was also a high risk of bias in several domains in <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>, including random sequence generation bias, allocation concealment bias, performance bias, detection bias, and reporting bias. Sensitivity analysis using a fixed‐effect model suggested that UFH may increase the risk of haemorrhagic events compared to control (RR 3.33, 95% CI 1.04 to 10.67; low certainty evidence). Due to small numbers of studies, funnel plots were not generated. Further research is very likely to have an important impact on our confidence in the estimate of effect of UFH and is likely to change the estimate. Overall, UFH may increase the risk of major bleeding (low certainty evidence). </p> <p>Separate analyses again suggested that any heparin (unfractionated or LMWH) may make little or no difference versus placebo to major bleeding events (RR 2.70, 95% CI 0.89 to 8.19; I² = 0%; low certainty evidence). The certainty of this evidence is low because only three small studies reported this outcome. Also, there is high risk of bias in several domains in <a href="./references#CD011557-bbs2-0006" title="UbhiCS , LamFT , MavorAI , GilesGR . Subcutaneous heparin therapy for cyclosporine-immunosuppressed renal allograft recipients. Transplantation1989;48(5):886-7. [MEDLINE: 2815265]">Ubhi 1989</a>. <a href="./references#CD011557-bbs2-0005" title="OsmanY , KamalM , SolimanS , SheashaaH , ShokeirA , Shehab el-DeinAB . Necessity of routine postoperative heparinization in non-risky live-donor renal transplantation: results of a prospective randomized trial. Urology2007;69(4):647-51. [MEDLINE: 17445644]">Osman 2007</a> had a high risk of performance bias and inclusion bias: when we re‐analysed the data in a sensitivity analysis, using a fixed‐effect model, heparin appeared to increase the risk of haemorrhagic events compared to control (RR 3.03, 95% CI 1.02 to 8.96; low certainty evidence). Due to the small numbers of studies, funnel plots were not generated. Overall, heparin may increase the rate of major bleeding (low certainty evidence), but further research is very likely to have an important impact on this conclusion. The effect of LMWH remains unclear (very low certainty evidence). </p> <p>Heparin had an unclear effect on the risk of readmission to intensive care (RR 0.68, 95% CI 0.12 to 3.90; I² = 45%; very low certainty). The individual studies varied in effect size and direction; I² was 45%, suggesting there may be moderate heterogeneity present between the studies however, this did not reach significance (P = 0.16) and is likely underpowered given the low number of studies with small sample sizes. Consequently, the 95% CIs in this meta‐analysis are large and interpretations should be cautious. </p> <p>In kidney transplant recipients the effect of heparin versus control on death, non‐graft thrombosis, and blood transfusion requirements is uncertain (all very low certainty evidence). </p> <p>Three studies investigated antiplatelet interventions in kidney transplant recipients (<a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>; <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>). The two studies by Zhang only included patients with a confirmed diagnosis of acute rejection, and the aims were to investigate the effects of platelet aggregation on acute rejection. <a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a> had high risk of selection bias, and the risk of selection bias in <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a> was unclear. </p> <p>No studies investigating antiplatelet interventions reported on early graft thromboses; RCTs are required. </p> <p>There is currently insufficient evidence to indicate an effect of aspirin compared with dipyridamole on the risk of major bleeding events or blood transfusion requirements (very low certainty evidence). In <a href="./references#CD011557-bbs2-0002" title="KauffmanHM , AdamsMB , HebertLA , WalczakPM . Platelet inhibitors in human renal homotransplantation: randomized comparison of aspirin versus dipyridamole. Transplantation Proceedings1980;12(2):311-4. [MEDLINE: 6771905]">Kauffman 1980</a>, there were seven gastrointestinal haemorrhagic events in the buffered aspirin group (20) whereas there were no gastrointestinal haemorrhagic events in the dipyridamole group (22) (P &lt; 0.01). This was a small study and they did not describe how a gastrointestinal bleed was defined. Furthermore, there was a high risk of bias in several domains, including random sequence generation bias, allocation concealment bias, performance bias, and detection bias. More studies comparing bleeding complications of aspirin with dipyridamole are required. </p> <p>Two studies reported on Lipo PGE<sub>1</sub> plus low dosage heparin therapy versus control (<a href="./references#CD011557-bbs2-0008" title="ZhangY , GuanD , XiaC , HanZ , XuJ , GaoJ , et al. Clinical study on Lipo PGE, inhibiting platelets activation in acute rejection after kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):163. [CENTRAL: CN-00509578] ZhangY , GuanDL , XiaCQ , HanZY , XuJJ , GaoJZ , et al. Clinical study of Lipo PGE1-inhibiting platelet activation in acute rejection after kidney transplantation. Transplantation Proceedings2005;37(10):4208-10. [MEDLINE: 16387079]">Zhang 2005</a>; <a href="./references#CD011557-bbs2-0009" title="ZhangY , ZhangXD , MaLL , GuanDL . Relationship between platelet activation and acute rejection after renal transplantation. Transplantation Proceedings2009;41(5):1547-51. [MEDLINE: 19545676]">Zhang 2009a</a>). These studies only reported graft survival and death as outcomes; the impact of Lipo PGE<sub>1</sub> plus low dosage heparin therapy on these outcomes remains unclear (very low certainty). </p> <p>There is insufficient evidence to assess an impact of heparin and citrate anticoagulation in preoperative haemodialysis (very low certainty). <a href="./references#CD011557-bbs2-0003" title="KikicZ , LorenzM , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. Effect of hemodialysis before transplant surgery on renal allograft function--a pair of randomized controlled trials. Transplantation2009;88(12):1377-85. [MEDLINE: 20029334]KikicZ , MatthiasL , Sunder-PlassmannG , SchillingerM , RegeleH , GyoriG , et al. The effect of hemodialysis and dialysis anticoagulation before transplant surgery on early renal allograft function - a pair of randomized controlled trials [abstract no: P-360]. Transplant International2009;22(Suppl 2):184. [CENTRAL: CN-01912347] ">Kikic 2009</a> did not report on early‐graft thromboses or non‐graft thromboses. Seven bleeding complications occurred in each of the heparin (66) and citrate (44) groups (P = 0.56). One‐year death‐censored graft survival rates were 88% in the heparin group and 90% in the citrate group (P = 0.44). </p> </section> <section id="CD011557-sec-0088"> <h4 class="title">Liver transplantation</h4> <p>Overall, there is insufficient evidence to guide the use of aspirin, warfarin, and pre‐transplant plasmapheresis (plus postoperative anticoagulation) as thromboprophylactic therapies in liver transplantation (very low certainty evidence). No meta‐analyses could be performed as only two studies (<a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a>; <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a>) investigating two different approaches were included. In addition, only conference abstracts for these studies could be obtained. </p> <p><a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> investigated aspirin versus warfarin therapy post‐transplant in patients with pre‐existing portal vein thromboses. There were no portal vein rethromboses in either group, and there were two deaths in the warfarin group due to bleeding complications (one with intracranial haemorrhage and one with internal bleeding) and none in the aspirin group. The authors concluded that aspirin is sufficient to prevent portal vein thrombosis. <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> had a high risk of random sequence generation bias (no randomisation approach detailed) and detection bias (lack of blinding), with unclear bias in most other domains. </p> <p><a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> investigated the impact of pre‐transplant plasmapheresis plus post‐transplant anticoagulation therapy versus postoperative low dose aspirin ± LMWH. They focused exclusively on patients with antiphospholipid antibodies or positive lupus anticoagulant, who they also deemed to be at high risk of thrombosis (9.0% of screened patients). The rate of "thrombotic complications" (not defined) was 37.9% in aspirin ± LMWH group and 10.3% in plasmapheresis group (P &lt; 0.0001). However, this study was found to be at high risk of bias in most domains. There was no description of methods of randomisation with different numbers in each group (12 and 17). They also gave no definition of "thrombotic complications". Impact on graft survival was unclear (P = 0.41; very low certainty). There were more deaths in the aspirin ± heparin group than the plasmapheresis group (5/12 and 2/12 respectively, P = 0.09). Overall, the study offered insufficient data to indicate a thromboprophylactic effect of either treatment arm (very low certainty evidence). </p> <p>Neither <a href="./references#CD011557-bbs2-0004" title="MansourianM , KazemiK , NikeghbalianS , ShamsaefaarA , ShafieeM , FakharN , et al. Prevention of portal vein rethrombosis after orthotopic liver transplantation: aspirin or warfarin? [abstract]. Experimental &amp; Clinical Transplantation2014;12(Suppl 2):270. [EMBASE: 71976559]">Mansourian 2014</a> or <a href="./references#CD011557-bbs2-0007" title="VillamilA , BandiJC , NunezF , MullenEG , YamamotoL , De SantibanesE , et al. Antiphospholipid antibodies associated vascular events are an underrecognized cause of morbidity and mortality after liver transplantation: benefit of plasmapheresis and anticoagulation in transplanted patients with high thrombotic risk [abstract]. Hepatology2016;64(1 Suppl 1):494A. [EMBASE: 612594651]">Villamil 2016</a> reported bleeding complications, hospital stay, blood transfusion requirements, or readmissions to intensive care. </p> <p>The role of thromboprophylaxis will differ depending on the risk profile of liver transplant recipients. Those in procoagulable states (such as those with antiphospholipid antibodies) most likely require different regimens to those who are coagulopathic, such as patients in acute liver failure. </p> <p>No RCTs were identified that investigated thromboprophylactic therapies in recipients of any other solid organ transplantation (e.g. heart, lung, pancreas, bowel, uterine or limb). Further research is needed in these areas. </p> </section> </section> <section id="CD011557-sec-0089"> <h3 class="title" id="CD011557-sec-0089">Overall completeness and applicability of evidence</h3> <p>Only kidney and liver transplant studies could be found which considered thromboprophylactic interventions and met inclusion criteria. Thus, the benefits and risks of anticoagulant and antiplatelet therapy remains uncertain in the wider context of solid organ transplants. More research is needed to make confident conclusions about the efficacy and risks of anticoagulant and antiplatelet interventions in solid organ transplants. </p> </section> <section id="CD011557-sec-0090"> <h3 class="title" id="CD011557-sec-0090">Quality of the evidence</h3> <p>We assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD011557-bbs2-0019" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924-6. [MEDLINE: 18436948]">GRADE 2008</a>; <a href="./references#CD011557-bbs2-0020" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [MEDLINE: 21195583]">GRADE 2011</a>). As shown in the <a href="./full#CD011557-tbl-0001">summary of findings Table 1</a>, the quality of the evidence was low to very low. Selection bias was high or unclear in eight of the nine studies; five studies were at high risk of bias for performance and/or detection bias; while attrition and reporting biases were in general low or unclear. Seven studies were in kidney transplant recipients and two studies were in liver transplant recipients. Studies were performed between 1975 and 2016; two studies were only reported as conference abstracts (both liver transplant recipients); and the number of participants randomised was small (range 29 to 220). Only three kidney transplant studies could be meta‐analysed. </p> <p>For the three outcomes that could be meta‐analysed, the certainty of the evidence was either low (<a href="./references#CD011557-fig-0004" title="">Analysis 1.1</a>: Major bleeding events: UFH; <a href="./references#CD011557-fig-0005" title="">Analysis 1.2</a>: Major bleeding events: all heparin) or very low (<a href="./references#CD011557-fig-0006" title="">Analysis 1.3</a>: Readmissions to intensive care: all heparin). Other outcomes of interest were graded as very low certainty (early graft thrombosis, blood transfusion requirements, graft and patient survival, and non‐graft thrombosis) as they were either not reported or were reported in such a way as they could not be meta‐analysed. </p> </section> <section id="CD011557-sec-0091"> <h3 class="title" id="CD011557-sec-0091">Potential biases in the review process</h3> <p>We attempted to limit biases at every stage in our review process, following guidance from the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD011557-bbs2-0025" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Two independent authors screened the identified studies prior to inclusion in the review. A standardised data extraction form was used to collect data from included studies. This was done independently by two authors, and any discrepancies were resolved by a third author. </p> <p>The risk of bias in locating studies is low. There were no arbitrary search limiters such as geographical location of study, or year of publication. The database search was extensive. For example, it included monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and handsearching of kidney‐related journals and the proceedings of major kidney conferences in addition to MEDLINE searches. </p> <p>The risk of bias in synthesising studies is low. All outcomes of meta‐analyses have been reported on, irrespective of statistical significance. </p> </section> <section id="CD011557-sec-0092"> <h3 class="title" id="CD011557-sec-0092">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD011557-bbs2-0038" title="Sáez-GiménezB , BerasteguiC , LoorK , López-MeseguerM , MonforteV , BravoC , et al. Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. Transplantation Reviews2014;29(2):85-92. [MEDLINE: 25573688 ]">Sáez‐Giménez 2014</a>, in their solid organ transplantation review, reported that studies evaluating epidemiology (<a href="./references#CD011557-bbs2-0037" title="PoliD , ZanazziM , AntonucciE , BertoniE , SalvadoriM , AbbateR , et al. Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. Journal of Thrombosis &amp; Haemostasis2006;4(5):988-92. [MEDLINE: 16689749]">Poli 2006</a>) in kidney transplantation did not show differences between those patients receiving no prophylactic treatment and those with prophylaxis (e.g. heparin followed by antiplatelet agents or heparin for 3 months). This agrees with conclusions in this review that prophylactic heparinisation and antiplatelet interventions are not recommended due to the uncertain nature of available evidence. No other systematic reviews have been identified however, a retrospective study (<a href="./references#CD011557-bbs2-0016" title="FriedmanGS , Meier-KriescheHU , KaplanB , MathisAS , BonominiL , ShahN , et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation2001;72(6):1073-8. [MEDLINE: 11579303]">Friedman 2001</a>) reported reductions in expected incidence of allograft thrombosis in renal transplant recipients following intravenous heparin treatment in patients with hypercoagulable states. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011557-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/urn:x-wiley:14651858:media:CD011557:CD011557-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011557-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_t/tCD011557-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011557-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/urn:x-wiley:14651858:media:CD011557:CD011557-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011557-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_t/tCD011557-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011557-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/urn:x-wiley:14651858:media:CD011557:CD011557-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011557-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_t/tCD011557-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011557-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/urn:x-wiley:14651858:media:CD011557:CD011557-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 1: Major bleeding events: unfractionated heparin" data-id="CD011557-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_t/tCD011557-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 1: Major bleeding events: unfractionated heparin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references#CD011557-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011557-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/urn:x-wiley:14651858:media:CD011557:CD011557-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 2: Major bleeding events: all heparin" data-id="CD011557-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_t/tCD011557-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 2: Major bleeding events: all heparin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references#CD011557-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011557-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/urn:x-wiley:14651858:media:CD011557:CD011557-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 3: Readmissions to intensive care: all heparin" data-id="CD011557-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_t/tCD011557-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Heparin versus placebo in kidney transplant recipients, Outcome 3: Readmissions to intensive care: all heparin </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references#CD011557-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/media/CDSR/CD011557/image_n/nCD011557-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011557-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus placebo for preventing thrombosis in kidney transplant recipients</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Heparin versus placebo for preventing thrombosis in kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> kidney transplant recipients<br/><b>Setting:</b> Australia, Egypt, UK<br/><b>Intervention:</b> heparin<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with heparin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early graft thrombosis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>Very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported no difference between groups.</p> <p>Effect on early graft thrombosis remains unclear</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events: unfractionated heparin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1,000<br/>(33 to 359) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.92<br/>(0.89 to 9.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unfractionated heparin may increase the risk of bleeding events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events: all heparin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>101 per 1,000<br/>(33 to 307) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.70<br/>(0.89 to 8.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All heparin may increase the risk of bleeding events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Readmissions to intensive care: all heparin</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1,000<br/>(15 to 488) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.68<br/>(0.12 to 3.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effect on readmission to intensive care remains uncertain</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blood transfusion requirements</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One study reported no difference between groups</p> <p>Effect on blood transfusion requirements remains unclear</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft and patient survival</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies comparing heparin with control reported on graft or patient survival</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐graft thrombosis</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>See comments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two studies reported no significant differences between groups</p> <p>Effect on non‐graft thrombosis remains unclear</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Heparin versus placebo for preventing thrombosis in kidney transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/full#CD011557-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011557-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo in kidney transplant recipients</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Major bleeding events: unfractionated heparin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.89, 9.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Major bleeding events: all heparin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [0.89, 8.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Readmissions to intensive care: all heparin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.12, 3.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo in kidney transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011557.pub2/references#CD011557-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011557.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011557-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011557-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011557-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011557-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD011557-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011557-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011557-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011557-note-0003">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011557-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011557\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011557\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011557\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011557\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011557\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011557.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011557.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011557.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011557.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011557.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724827088"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011557.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724827092"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011557.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6c532956f4ca',t:'MTc0MDcyNDgyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 